Dr. Susan C. Scott

Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an associate professor of oncology for Johns Hopkins University School of Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital. Dr. Levy is a physician scientist who is interested in innovative immunotherapeutic approaches for advanced stage lung cancer patients and biomarkers that help define those patients more likely to respond to such agents. He has an expertise in thoracic malignancies, including non-small cell lung cancer, small cell lung cancer and thymic malignancies, as well as head and neck cancer. Dr. Levy earned his medical degree from Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Center, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his clinical research in prostate cancer. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, medical director of thoracic oncology for Mount Sinai Health Systems and associate director of the Cancer Clinical Trials Office for Mount Sinai Hospital in New York City. Dr. Levy played an integral role on several American Society of Clinical Oncology (ASCO) committees and currently serves as associate editor for the ASCO University Committee. He completed a two year term on the editorial board for the Journal of Clinical Oncology and currently serves as an ad hoc reviewer for other journals, including Clinical Lung Cancer, The Oncologist and Oncotarget. Dr. Levy was recently selected as one of only 15 oncologists in the country to the prestigious ASCO Leadership Development program, whose mission is to identify and develop future leaders of ASCO. In addition to his ASCO commitments, Dr. Levy serves on the ALLIANCE Respiratory Committee, the IASLC Staging Committee and the IASLC Career Development & Fellowship Committee. Dr. Levy is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Janakiraman Subramanian is an Oncologist and a Hematologist in Fairfax, Virginia. Dr. Subramanian is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Subramanian is currently accepting new patients.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Elite provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).